Australia to host clinical trial of nasal spray vaccine to fight COVID-19

An Australian contract research organization, Avanche Clinical, has made a revolutionary attempt for the globe’s war against COVID-19, with its announcement of conducting the first clinical trial of a genetically altered adenovirus vaccine for the infection via nasal spray.

As per credible sources, the organization has already proposed the idea to the office of the gene technology watchdog for permission to conduct the Phase 1 clinical trial on behalf of Tetherex Pharmaceuticals Corporation.

Apparently, the clinical trial would be conducted on men and women aged between 18 to 55 years with no history of blood clot disorders.

The trial, which is estimated to run from June to September 2021, proposes making use of genetic modification to prevent the coronavirus infection to multiply and insert a gene encoding Sars-Cov-2 spike protein to help people produce antibodies against coronavirus.

Moreover, the trial also proposes importing a genetically modified human adenovirus from the US to clinical trial facilities and sites, including CMX, Nucleus Network, Scientia, and Linear.

The proposal seeks approval for upto 1000 healthy participants to be dosed at these sites and hospitals in Australia, although the data offered to the federal government claims its enrollment will be nearly about 40 people. In fact, the application rates the risk from the trial as ‘negligible’.

It was mentioned in a statement that the preclinical studies have demonstrated that vaccination trials for nasal sprays in animal models has shown good efficiency and no major adverse side effects and reactions.

For the record, adenoviruses modified for nasal spray are a promising field for the 2nd generation of COVID-19 vaccines, potentially alleviating the infection spread through sprays with less strict refrigeration norms and mandates.

Importantly, nasal spray vaccine candidates are also being developed by a US firm, Altimmune, a joint venture between AstraZeneca and Bharat Biotech in India and Washington University.

Source Credit: